CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Evelo Biosciences Issued With U.S. Patent For Pharmaceutical Compositions of Veillonella Parvula Bacteria

Life Sciences Review Life Sciences Review | Tuesday, September 21, 2021
Tweet

Evelo Biosciences' new patent claims encompass Veillonella parvula oral formulations and are an addition to the company's increasing intellectual property (I.P.) portfolio for SINTAX therapies.


FREMONT, CA: Evelo Biosciences announces that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medications, including pharmaceutical formulations of Veillonella parvula bacteria.


"The grant of this patent is further confirmation that pharmaceutical compositions containing single strains of naturally occurring bacteria selected for their potential therapeutic properties are patent-eligible," said Dr. Mark Bodmer, Chief Scientific Officer and President of R&D of Evelo. "These compositions do not occur in nature and so are patentable in a similar way to more conventional novel medicines. We are pleased that this has again been recognized by the U.S. Patent and Trademark Office, providing vital I.P. covering for Evelos leading innovation in developing effective, safe, oral SINTAX medicines."


This patent is an important addition to the Company's significant and increasing intellectual property (I.P.) portfolio for SINTAX therapies that target the small intestinal axis. This new patent's issued claims encompass Veillonella parvula oral formulations, including EDP1867, which is now being tested in a Phase 1b clinical trial for the treatment of atopic dermatitis.


"The patent specification also discloses the use of extracellular vesicles (E.V.s) derived from Veillonella as orally-delivered medicines," continued Dr. Bodmer. "Preclinical data suggest that E.V.s may be effective as oral gut-restricted medicines with systemic effects. Their physical properties may enable increased engagement of the small intestinal axis and, so, increased efficacy. Our first E.V. product candidate, EDP2939, is on-track to enter the clinic in 2022 as part of the continuing expansion of Evelos product portfolio and its underlying I.P."


Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered medicines that act on SINTAX, the small intestinal axis, to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.


Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 to treat inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/evelo-biosciences-issued-with-us-patent-for-pharmaceutical-compositions-of-veillonella-parvula-bacteria-nwid-568.html